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While timelines for clinical development have been extensively studied, there is little data
on the broader path from initiation of research on novel drug targets, to approval of drugs
based on this research. We examined timelines of translational science for 138 drugs and
biologicals approved by the FDA from 2010–2014 using an analytical model of technology
maturation. Research on targets for 102 products exhibited a characteristic (S-curve) maturation pattern with exponential growth between statistically defined technology initiation and
established points. The median initiation was 1974, with a median of 25 years to the established point, 28 years to first clinical trials, and 36 years to FDA approval. No products were
approved before the established point, and development timelines were significantly longer
when the clinical trials began before this point (11.5 vs 8.5 years, p<0.0005). Technological
maturation represents the longest stage of translation, and significantly impacts the efficiency of drug development.
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There is little theoretical understanding why the many dramatic advances in biomedical science in recent decades have not produced proportional growth in the number of new therapies. The problem is well documented; the annual number of approvals of New Molecular
Entities (NMEs) has been static [1], clinical development pipelines continue to have high attrition rates [2], and drug development costs are increasing exponentially [3]. While there has
been extensive analysis of the clinical and regulatory stages of drug development [2, 4, 5], less
is known about the basic and applied research stages of translational science that provide constructive insights into mechanisms of health and disease, identification of potential drug targets, or the initial discovery of promising lead compounds.
Evidence suggests that the inefficiency of these early stages may be limiting the pace of
translational science. The FDA and others have noted the lack of growth in the number of
drug approvals reflects an underlying paucity in the number of candidate products in the
clinical pipeline. Similarly, the President’s Council of Advisors on Science and Technology
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(PCAST) identified lack of validated targets as a major barrier to building robust clinical pipelines and developing new cures [6].
There has been little empirical or theoretical work on these early stages of translational science. Much of the existing literature is anecdotal, describing experiential insights into the
obstacles and opportunities encountered by individuals or companies engaged in target validation, high-throughput screening, lead identification, or preclinical testing. Often, these analyses address the challenges of entrepreneurship and financing, rather than how scientific
insights are translated into products [4].
Theories of innovation arising from other technology sectors suggests that the ability to
design and develop successful products is often dependent on a high degree of technological
maturity [7–9]. Innovation research shows that technologies classically mature through a technology growth cycle, which can be quantitatively modelled as an “S-curve”. This research
shows that novel technologies arise from precursor studies through scientific insights or inventions, which initiate a period of exponential technical growth. As this new technology advances
and becomes established, technological progress slows and approaches a limit. Beyond this
point, technological progress comes predominantly through the initiation of new technologies
which mature through a new cycle of growth. The critical observation is that, while nascent
technologies embody the promise of superior product performance, early stage technologies
commonly fail to generate products that can meet the performance or market standards set by
more mature, established technologies [8, 9]. It is not until new technologies achieve a certain
level of technological maturity that they consistently produce products that can meet, or redefine, these standards.
Bibliometrics uses the accumulation of knowledge in a defined field, measured by number
of PubMed entries, as a metric for technological growth and maturation. Studies have shown
that the accumulation of publications commonly exhibits a characteristic S-curve growth pattern similar to that seen for other technologies [10], and that this growth can be modeled as an
exponentiated logistic function, which we have named the Technology Innovation Maturation
Evaluation (TIME) model.
This model provides statistically-defined metrics for both the point of initiation of new
technologies and the point at which these technologies may be considered established (Fig 1).
The initiation point is calculated as the date of maximum acceleration of publication activity,
corresponding to the beginning of a period of exponential growth. The established point is calculated as the point where exponential growth ends, and there is maximum slowing of publication activity. The initial studies with this model showed that development programs involving
monoclonal antibodies, nucleotide therapies, and gene therapies that were undertaken early in
the growth cycles of these technologies uniformly failed, and that successful lead compounds
entered clinical development only after the associated technology approached the established
point [10, 11]. A similar pattern was observed for cancer therapeutics, where the many scientific and technological advances of the 1970s and 1980s generated few targeted or biological
products until these technologies passed established point [12]. Significantly, no such association was seen for phenotypically discovered products, consistent with the fact that understanding of the targets or mechanism of action of phenotypic products is often unknown when
the compound is discovered, and often follows from identification of bioactive compounds
[13–16].
In the present work, we used this model to examine the timelines of translational science
for the 138 new drugs and biological products approved by the FDA from 2010–2014. The
goal of this work was to make an objective assessment of the time required for biomedical discoveries to be translated into successful biopharmaceutical products using state-of-the-art discovery and development technologies and within the contemporary regulatory environment.
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Fig 1. The TIMEtm model technology growth cycle. Top: Technology maturation is modeled as a best-fit,
exponentiated logistic regression to the cumulative number of publications (N) over time. Bottom: The second
derivative of this regression is used to identify the initiation point (point of greatest acceleration, d2log(N)/dx2 =
max) and established point (point of maximal deceleration, d2log(N)/dx2 = min) for the technology. The
initiation and established points bound a period of exponential growth, which subsequently slows as the
technology approaches its limits.
https://doi.org/10.1371/journal.pone.0177371.g001

By doing so, we hoped to identify patterns of innovation in biopharmaceutical development as
well as quantifiable milestones that might inform more efficient translational strategies, investments, and policies that could accelerate the translation of scientific discoveries for public
benefit.

Results
Modeling the technology growth cycle
We identified 138 NMEs approved by the FDA from 2010 through 2014, excluding imaging
agents, diagnostics, and reformulations or combinations of previously approved molecular
entities. Of the 138 NMEs studied, 18 were approved in 2010, 25 in 2011, 37 in 2012, 20 in
2013 and 38 in 2014. This dataset of recently approved drugs best-reflects contemporary discovery and development practices and regulatory policies. The last decade has seen many
innovations in regulatory science including safety science, adaptive clinical trial design and
the use of biomarkers. Additionally, there has been widespread application of novel screening
and research techniques, such as RNAi, genomics, rational drug design and microfluidic
screening as well as novel chemical entities including the first bispecific antibody and antisense
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therapeutic. Finally, drug development has also been influenced by pressure from payers to
demonstrate superior efficacy over existing drugs for pricing and reimbursement purposes
[17, 18]. While the development and regulatory landscape continues to change, analysis of this
most-recent period provides the best approximation of current practices.
Each NME was classified as “phenotypic”, “targeted”, or “biologic” based on the methods
used for drug discovery or the molecular composition as described by Swinney [19]. Briefly,
phenotypic products are discovered by screening for biological activities, without reference to
a specific target or mechanism of action. In contrast, targeted drugs are discovered through in
vitro assays involving specific targets or hypotheses regarding the molecular mechanism of
action and require an understanding of the underlying biology in order to develop a molecule.
Biologics include monoclonal antibodies (mAbs) as well as recombinant versions, or analogues, of natural bioactive proteins and are discovered by a process analogous to targeted
screening. Using the classifications of drugs included in the work by Swinney [19], and applying their method to classify more recently approved drugs, provided an objective way to identify classes of drugs whose discovery was predicated on advancing knowledge of a drug target
or disease mechanism, as well as those that might have been discovered independent of this
knowledge [13–16]. Our hypothesis is that successful development of targeted and biological
therapeutics would correlate with metrics of technological maturation, while no such relationship would be evident for phenotypic products. Of the 138 NMEs examined, 34 were classified
as phenotypic, 64 classified as targeted, and 40 classified as biologics (S1 Table).
The technology associated with each NME was defined as the target used in screening
assays for small molecule drugs or mAbs, the target of phenotypic NMEs (if known), or the
natural counterpart of the protein comprising a non-mAb biologic. A unique target or natural
biological entity was identified for 121 NMEs. For 17 phenotypic NMEs, the molecular target
could not be unequivocally identified in the literature. PubMed searches were performed for
each technology to quantify the accumulation of publications over time. The list of NMEs,
associated target technologies and Boolean search terms is shown in S1 Table.
Technology growth curves were modeled as an exponentiated logistic regression (S-curve)
using methods described previously. Target technologies associated with 102 products fit this
model using goodness of fit measures (see Materials and methods). For each of these technologies, the initiation and established points bounding the exponential growth phase were determined (Fig 1, S1 Table)). Target technologies associated with 19 products did not exhibit a
logistic growth pattern and were not further characterized. Sample curves are shown in S1 Fig.
The technology initiation points for targets associated with 102 NMEs are shown in Fig 2.
The median initiation was in 1974. Of these, 91/102 NMEs were associated with targets that
had an initiation point before 1985. For some NMEs, the initiation point corresponds with the
publication date of works that described a specific target or gene product for the first time. For
example, simeprevir (Olysio) and sofosbuvir (Sovaldi) are targeted to the hepatitis C virus
polyprotein, which had a statistically defined initiation point of 1986. This date corresponds
with the period between reports describing purification of the virus associated with “non-A
non-B” hepatitis in 1985 [20] and the cloning of the viral genome in 1989 [21]. For others, the
initiation point corresponds to the date of scientific advances that enabled target discovery.
For example, ivacaftor (Kalydeco) is targeted to the Cystic Fibrosis Transmembrane Conductance (CFTR) protein (a chloride channel), discovered in the mid-1980s through genetic linkage studies and studies of ion transport. The statistically defined initiation point for CFTR was
1976, which corresponds in time with early genetic linkage studies using classical genetic
markers [22]. Thus, the calculated initiation point recognizes that the technology growth cycle
for CFTR did not begin with the isolation of this gene. Rather, the technology growth cycle
was initiated by earlier research on biological processes that are associated with this protein,
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Fig 2. Initation (Ti) years for technologies associated with NME approvals 2010–2014. The distribution
of technology initiation years for the drug target or biological entity associated with 102/138 NMEs approved
by the FDA between 2010 and 2014.
https://doi.org/10.1371/journal.pone.0177371.g002

and the association of this locus with Cystic Fibrosis, and was already advancing exponentially
when CFTR, itself, was identified. Considering non-genome based research, icabitant (Firazyr)
is a bradykinin receptor B2 antagonist, used to treat acute attacks of hereditary angioedema.
The initiation point for research on this target was 1980, which corresponds to early publications describing binding of bradykinin to the B2 receptor [23]. Similarly, tesamorelin (Egrifta)
is a synthetic growth hormone releasing hormone, approved for reduction of excess belly fat in
HIV infected patients. The initiation point for this biological product was 1967, which corresponds to publications describing the purification of GHRH from pigs and its biological effects
in animal models [24].

The timeline from initiation to drug approval
Fig 3 shows the timelines for translational science calculated from the initiation point. The
median interval from the initiation to established points was 25 years (Fig 2A), the median
interval from initiation to the start of clinical trials was 29 years (Fig 2B), and the median time
from initiation to first approval was 36 years (Fig 2C). We did not observe any significant
differences in these timelines for small molecules compared to biologics. The median time
between the start of clinical trials and first approval for the NMEs in this study was 8 years
(range 4 to 20, average = 9.4). These clinical development timelines are in line with previous
reports [2].
Other studies have characterized the timeline of translational science starting with the publication dates of generally recognized seminal papers. Cockburn and Henderson examined
a set of 21 drugs with the high therapeutic impact approved between 1965 and 1992 and
reported that the average time from the “key enabling discovery” (i.e. fist report describing
activity in a screen for phenotypic drugs or first description of a mechanism for “mechanism
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Fig 3. Time interval between technology initiation and metrics of translational science. (A) Time
interval between technology initiation (Ti) and established (Te) years. (B) Time interval between technology
initiation and start of clinical trials. (C) Time interval between technology initiation and first drug approval. The
median and quartile boundaries are shown for all technologies with initiation after 1950.
https://doi.org/10.1371/journal.pone.0177371.g003

based,” targeted drugs) to market introduction was 25 years [25]. More recently, Eder et al.
examined the interval from selected publications that described target or lead identification, to
FDA approval for first in class drugs from 1999–2013 and reported a median interval of 22
years [26]. Our data set includes 40 of the first-in-class products studied by Eder as well as
10 follow-on products to those included in that study. There is a high degree of correlation
between the statistically defined initiation point and the first publication empirically identified
by Eder (t-test, p<1x10-5), though there was a 12 year average difference in these dates (t-test
with hypothesized mean difference = 12 years, p< t-test, p<10−12) (data not shown). This
interval is consistent with the observation that the statistically-defined initiation point corresponds to scientific discoveries or inventions that may precede, and enable, subsequent
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Table 1. Number of new chemical entities approved by the FDA 2010–2014 and average years in clinical trials when the first clinical trials were performed before the target technology was established (before Te) or after the technology was established (after Te).
Type

all

before Te

after Te

# of compounds (2010–2014)

all

before Te

after Te

p

# years in clinical trials (average)

All*

102

29

73

9.4

11.5

8.5

0.0003

Pheontypic

15

5

10

10.7

13.0

9.5

0.2NS

First-in-class

53

18

35

9.8*

9.5

8.7

0.003

Follow-on

49

12

37

8.9*

11

8.3

0.01

Targeted (NCE)+Biologic

87

24

63

9.4

11.5

8.5

0.00004

Targeted (NCE)

54

13

41

8.4

10.2

7.8

0.01

Biologic

33

11

22

10.2

12.4

9.3

0.003

Data are shown for 102 of 138 compounds approved by the FDA between 2010 and 2014. Of the remaining compounds, 17 are phenotypic compounds with
an uncertain target/mechanism of action, and 19 exhibited a growth pattern that did not fit the exponentiated logistic model. p values from t-test.
*clinical timelines for first in class drugs compared to follow-on were not significantly different (t-test, p-value = 0.23)
NS = not significant
https://doi.org/10.1371/journal.pone.0177371.t001

identification of specific targets or lead compounds. Further research is required to more accurately map specific, technical milestones to the metrics of the technology growth cycle.

Impact of technological maturity on development
For 72/102, the start of clinical trials occurred after this established point (Table 1). We
observed a similar ratio for targeted NCEs, phenotypic NMEs, or biologics. This ratio was also
similar for first-in-class versus follow-on products (Table 1), consistent with the observation
that most recent follow-on products have overlapping clinical development timelines with the
first in class drug [27].
The length of time between the start of clinical trials and first approval was significantly
shorter for products that entered clinical trials after the established point, than for those that
entered development earlier (8.5 vs. 11.5, t-test, p<0.0005). The average difference was similar
for targeted NCEs, phenotypic NCEs, and biologicals (approximately 3 years), but was not statistically significant for the small number of phenotypic NCEs (Table 1).
We examined whether there were significant differences in the translational timelines
between first in class drugs and follow-on drugs approved from 2010–2014. As expected, the
follow-on drugs approved in this interval were associated with targets that had earlier initiation
points (median Ti first in class = 1978, follow-on = 1968), though there was no significant difference between the median Te for first in class drugs (2000) and follow-on drugs (1999). The
average time between the established point and initiation of clinical trials was longer for follow-on drugs, but the difference was not significant (first in class = 4.1 yrs, follow-on = 5.5yrs,
p = 0.37 (Table 1)). We would note that the time-delaminated study design means that the follow-on products do not correspond to first in class products in this study.

Discussion
Despite dramatic advances in biomedical science and concerted efforts to streamline the clinical and regulatory stages of drug development, the efficiency of clinical development remains
unchanged, and may actually be decreasing [1, 3–5]. At the same time, the cost of drug development continues to rise, with the most recent estimates average out-of-pocket cost for each
new compound reaching $1.4 billion and fully capitalized costs reaching $2.6 billion [28].
There is accumulating evidence that there are barriers to development occurring in basic and

PLOS ONE | https://doi.org/10.1371/journal.pone.0177371 May 8, 2017

7 / 13

Timelines of translational science

applied research, which generates novel targets, target validation, and enables the subsequent
stages of drug discovery and development. The PCAST report identified “rate-limiting knowledge gaps” that limited the number of compounds entering clinical development [4], while an
Institute of Medicine report identified a “translational block” in the “transfer of new understandings of disease mechanisms gained in the laboratory” to testing in humans [5]. The present work was undertaken to better understand the relationship between these early stages of
enabling research and the efficiency of subsequent development.
Our analysis is grounded in theories of innovation, which posit that new technologies
mature through a characteristic growth cycle (S-curve), and that the ability to develop successful products from such technologies is related to the level of maturity. Previous studies have
extended these principles to biopharmaceutical development [10, 11] using a bibliometricbased analytical model for the maturation of biomedical technologies. The present analysis
models the maturation of target-related technologies as a characteristic S-curve (exponentiated
logistic) and identifies the initiation point where exponential growth in publications begins as
well as an established point representing slowing of publication activity and end of exponential
growth in publication activity.
This work explicitly examines the timelines of translational science for NMEs approved by
the FDA between 2010 and 2014. We show that for the 138 NMEs approved in this interval,
there were 102 distinct targets, of which 90 exhibited a growth pattern that could be modeled
as an exponentiated logistic function with acceptable fit/error. Using this model, we observed a
strong association between maturity of the target technology and timelines of translational science for 102/138 NMEs approved from 2010–2014. There are two aspects to this observation.
First, the majority (73/102) only entered clinical trials after the target technology was established, and none of the NMEs approved 2010–2014 were approved before this point. We do
not know how many failures might be associated with the lack of maturity of the target technologies. We would caution that these data also do not establish a causal relationship between
the maturity of target technologies and clinical failure. Certain targets are traditionally considered “undruggable” due to their biochemical or biophysical characteristics, and some technologies, such as ribozymes, never generate therapeutic products. Moreover, clinical leads may
fail for many reasons unrelated to the target such as chemical instability, disadvantageous
pharmacokinetics, or idiosyncratic toxicities, and up to one third of leads may fail for “commercial” reasons related to the sponsor’s strategy or finances [2]. For example, data has shown
that the probability of success in phase 2 is significantly lower when the trials are sponsored by
smaller, biotechnology companies with limited capital resources [29]. Further studies, with
cohorts of failed compounds, are required to sort out the relative contribution of technological
maturity to development success or failure.
The data generated from this model also do not suggest that technological maturity is sufficient for success, and there is wide variation in the timelines observed between the established
point and first approval of NMEs associated with these technologies. A closer examination of
the four products that were approved within five years of the established point indicates that
two were phenotypic (dimethyl fumarate (Tecfidera) and fingolimod (Gilenya)). The other
two were denosumab (Prolia), a monoclonal antibody targeted against RANKL, a member of
the TNF family of proteins, and ruxolitinib (Jakafi), a small molecule targeted against JAK protein kinases. Both RANKL and JAK are members of large superfamlies of proteins that had
been successfully targeted with other therapeutics. More research is required to fully understand how the maturity of the target technology, the maturation of technologies related to the
chemical entity, and other information known to be associated drug development such as
Lipinski’s “rule of 5” [30] and AstraZeneca’s “5 R’s” [31],collectively contribute to the probability of successful development.
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Second, data from this model shows the timeline of clinical development averaged three
years shorter for products that entered clinical trials after the established point than for those
that entered clinical trials when the target technology was less mature. This result suggests that
the efficiency of clinical development was greater as the target technology passed the established point. To put the significance of this three year difference in context, DiMasi has examined the economic benefit of improving the timelines for drug development [32]. Based on his
calculations, and using the most recent estimates for the fully capitalized cost of drug development [28], the 3 year (27–35%) average difference in drug development timelines observed
here represents a cost differential of $100–200 million dollars in development costs. Many different factors may impact development timelines, ranging from the therapeutic area [33],
small molecules versus biologicals, and various tracks for FDA review including Orphan drug
designation, Expedited Drug Development, Accelerated Approval, Fast-Track designation,
Priority Review, and Breakthrough Designation. Our data shows no significant difference
between NCEs and biological products or between first in class drugs compared to follow-on
products, but further [19] research would be required to sort out the multiplex effects of these
factors on development timelines.
Analytical modeling of technology maturation provides an objective means for measuring
the timelines of translational science. While it is more common to measure translational
progress by tangible measures such as the dates of seminal publications or phases of clinical
investigation, such metrics are inherently biased by the differential transparency of research
performed in academic, start-up, or large corporate environments, differing standards for progressing through phased clinical trials based on the size or business models of the sponsoring
corporation, as well as the subjective nature of a posteriori assessments of the importance of
selected papers and milestones in successful development programs. Moreover, analytical metrics that might be calculated in real-time through the translational process have the potential
to provide strategic guidance for development decisions and planning. While we have not
explored the predictability of the current analytical model, the present results suggest that suitable metrics of technological maturity could be useful in handicapping the likelihood of clinical success and optimizing the timeline of clinical development.
This work focuses specifically on the maturation of technologies related to the drug target
or, in the case of biologics, the natural counterpart of the protein. It is likely, however, that a
complete picture of drug development requires a multifactorial analysis of technology related
to the target, target families chemical entity, disease association, and ancillary technologies for
production, delivery, and formulation. For example, we have previously examined the maturation of technologies related to monoclonal antibodies, gene therapies, and nucleotide therapeutics since the 1970s, showing that these technologies were successfully developed only after
achieving a requisite level of maturity [10].
In the context of this dataset and analytical model, it is of interest that there a clear association between the maturation of technology associated with the target and the efficiency of drug
development. We might speculate that this strong association with maturation of target-related
technology reflects the established state of many complementary technologies such as recombinant protein production, monoclonal antibodies and small molecules, many of which are
based on long-established chemistries, for example the “rule of 5” [30] We believe a multifactorial analysis of the different technologies that contribute to a drug would provide a more accurate description of the timelines of translational science [2].
The central observation in this work, namely the relationship between target technological
maturity and effective biopharmaceutical development, is not surprising. There is a colloquial
understanding that many clinical trials fail because the biology is “too complex” or “unpredictable”. While we do not yet fully understand the dynamics underlying the “S-curve” pattern of
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publications, we can postulate that the rate of publication continues to increase as long as new
research questions continue to emerge, and that publication activity begins to slow as more of
these questions are answered. Thus, the maximum slowing of publication activity at the established point could reflect the point at which the biology is no longer “too complex,” and quality
of target validation, lead identification, and clinical trial design improves significantly. These
data suggest that this is equally true for biological products as for small molecules.
This work emphasizes the importance of considering the complete timeline of translational
science from the initial insights or inventions that give rise to a new technology, through to the
launch of new products based on these technologies. The observation that the median time
from target technology initiation to first clinical entry was 3–4 times longer than the timeline
of clinical development, suggests that initiatives aimed at strategies for accelerating technology
maturation could have a proportionally greater effect on the rate of translational science than
those aimed exclusively at clinical development. Thus, research aimed at understanding the
dynamic nature of technology maturation and its relationship to successful product development should be a high priority. The present observations point to the critical importance of
consistent funding for nascent stage technologies to ensure their continued, unimpeded maturation, and also to the need for closer alignment between the basic and applied science that
contributes to the maturity of technologies, and the strategic needs of product development.

Materials and methods
Data sources
NMEs approved by the FDA between 2010 and 2014 were identified from FDA.gov. Timelines of clinical development from the first clinical entry for any indication, to FDA approval
were identified in PharmaProjects. To classify the NMEs as targeted, phenotypic, or biologic
we used the method described by Swinney [19]. Briefly, this method involves a literature
review to identify papers describing discovery of the lead compound. If the compound was
discovered using a targeted screen of a chemical or MAb library, or is a biological copy or
analogue of a naturally occurring biological product, the NME is classified as targeted.” If the
compound was discovered based on a biological activity in vivo or in cell culture, it is classified as “phenotypic.”
For each monoclonal antibody, targeted and phenotypic NME, the associated technology
was the drug target as identified in PharmaProjects or by a review of the literature. For biologics other than monoclonal antibodies, the associated technology was the biologic entity comprising, or analogous to, the product. Boolean search terms (S1 Table) were developed for each
technology and the annual number of publications in PubMed was determined. Numerical
modeling is performed from the first year of continuous publications identified in the literature, and excludes earlier publications separated by years with no publication activity. The
discontinuous data points are excluded to minimize bias associated with incomplete ascertainment of relevant papers in earlier years due to immature vocabularies and/or the absence of
abstracts. We have found that the early publication record is often very messy, and have chosen
a rule-based approach to minimize this bias.

Analytical modelling
An exponentiated logistic function was used to model publication growth:


N¼L
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Which also has the form:
log N ¼

log L
1 þ e rðt

t0 Þ

Where N is the number of publications, L is the presumed upper limit of publications, r is the
growth rate, t is time, and t0 is midpoint of exponential growth. The parameters were fit to
time series publication data using a non-linear least squares implementation of the LevenbergMarquardt algorithm, which can be found at: http://lmfit.github.io/lmfit-py/
This asymmetric sigmoidal function, exhibits the common logistic sigmoid function over
log scales. This gives it property of having a symmetric growth phase that is exponential on
average. The initiation and established points, representing the beginning and end of exponential growth or logN”(t)max,min (Fig 1) can be analytically determined by:
Established; Initiation ¼ t0 

acoshð2Þ
r

Standard errors from the Levenberg-Marquardt analysis were used to educate a MonteCarlo simulation of the fitted parameters. The average standard error of this simulation was
used as metric for goodness of fit. Generally, curve fits were considered to be valid if this error
metric was less than 10%.

Supporting information
S1 Table. List of NMEs approved from 2010–2014, associated target technologies, search
terms, molecular classification,technology timelines (Ti and Te) and clinical development
timeline. For this analysis, we have explored many different equations that might be used to
model technology growth, including functions fit to the cumulative number of publications
(exponential, logistic, Richardson, Gompertz, exponentiated logistic, and exponentiated Gompertz). Both the exponetiated Gompertz and exponentiated logistic functions fit the majority
of datasets examined. Both are routinely calculated in our analysis. We show the Ti, Te and
residual mean square error for both functions. For the technologies in this study, the average
residual mean square error was marginally better with the exponentiated Gompertz function
(199) than EL (226). Our preference for the exponentiated logistic function over the exponentiated Gompertz function is based on two “ground truth” experiments that are routinely performed when testing the applicability of the model. First, we search the literature for historical
review articles, and ask whether the estimated initiation point corresponds to seminal research
advances highlighted by experts in the field. We find that the estimate of initiation provided by
the exponentiated logistic model most often corresponds to seminal advances highlighted in
review articles. Second, based on the timelines described in review articles and the titles/
abstracts of articles identified in the PubMed search, we ask whether significant advances were
made before the estimated initiation point. Across all technologies studied, we find that the
estimates of initiation provided by the exponentiated Gompertz function often post-date an
extended period of rapid advance in the field.
(XLSX)
S1 Fig. Examples of technology growth curves. Markers show cumulative publication data
for a given technology from Pubmed. Solid line shows model of publication growth using an
exponentiated logistic function (see Methods for formula). Note that data are shown on a log
scale, so that residuals at the low end of the model (e.g. 101−102 papers) appear disproportionately large in this representation, but actually have smaller residuals, because of the very small
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numbers of papers, relative to the residuals at the high end when there are 103−105 papers.
(TIF)
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